Litigation Details for PROMETHEUS LABORATORIES INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2011)

« Back to Dashboard

PROMETHEUS LABORATORIES INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2011)

Docket		Date Filed	2011-01-14
Court	District Court, D. New Jersey	Date Terminated	2014-06-03
Cause	35:271 Patent Infringement	Assigned To	Kevin McNulty
Jury Demand	None	Referred To	Michael A. Hammer
Parties	ROXANE LABORATORIES, INC.
Patents	6,284,770
Attorneys	WILLIAM C. BATON
Firms	Sills Cummis & Gross
Link to Docket	External link to docket

Details for PROMETHEUS LABORATORIES INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2011)

Date Filed	Document No.	Description	Snippet	Link To Document
2011-01-14				External link to document

Prometheus Laboratories v. Roxane Laboratories: Entocort EC Patent Litigation Analysis

Last updated: August 3, 2026

Prometheus Laboratories Inc. v. Roxane Laboratories Inc., No. 2:11-cv-00230, was an ANDA patent case involving generic delayed-release budesonide capsules corresponding to Prometheus’s Entocort EC product. The litigation tested patents covering the product’s controlled-release formulation and treatment of ileal and ileocecal Crohn’s disease. The asserted patent claims were ultimately held invalid for obviousness, and the Federal Circuit affirmed the judgment against Prometheus. The decision reduced the patent barrier to generic budesonide delayed-release capsules and limited the commercial value of the Entocort EC patent estate. [1]

What drug and patents were involved in Prometheus v. Roxane?

The case concerned Entocort EC, an oral delayed-release formulation of budesonide used to induce remission in patients with mild to moderate Crohn’s disease involving the ileum and/or ascending colon.

Prometheus marketed Entocort EC in the United States after obtaining commercial rights to the product. Roxane filed an abbreviated new drug application seeking approval to market a generic version. Prometheus responded with a Hatch-Waxman patent-infringement action under 35 U.S.C. § 271(e)(2).

What was the Entocort EC formulation?

Entocort EC used budesonide-containing capsules designed to resist release in the stomach and upper gastrointestinal tract. The dosage form released budesonide in the terminal ileum and colon, where Crohn’s disease commonly affects patients.

The commercial product’s value depended on more than the active ingredient. Budesonide itself was an established corticosteroid. The relevant patent position focused on:

• Delayed or controlled release of budesonide.
• Delivery to the terminal ileum and colon.
• Use of the formulation for treating Crohn’s disease.
• Pharmaceutical dosage-form characteristics that limited early release.

The litigation therefore involved formulation and method-of-use protection rather than a new-molecule patent.

Which patents did Prometheus assert?

The litigation involved patents listed in connection with Entocort EC and directed to budesonide controlled-release technology. The principal patent issues concerned whether the claimed formulation and treatment method represented a non-obvious advance over earlier budesonide formulations and publications.

The district court and Federal Circuit evaluated the asserted claims as a group against the prior art. The appellate decision focused on obviousness, the scope of the claims, and whether the prior art provided a reason to combine known formulation teachings. [1]

When did Prometheus file the Roxane patent lawsuit?

Prometheus filed the action in the U.S. District Court for the District of New Jersey in 2011. The case was assigned civil action number 2:11-cv-00230.

The filing followed Roxane’s ANDA submission and its Paragraph IV certification. Under the Hatch-Waxman framework, a Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. Prometheus’s lawsuit triggered the statutory 30-month stay of FDA approval for the challenged ANDA, subject to statutory exceptions and court developments.

Item	Case detail
Plaintiff	Prometheus Laboratories Inc.
Defendant	Roxane Laboratories Inc.
Court	U.S. District Court for the District of New Jersey
Civil action	No. 2:11-cv-00230
Filing year	2011
Regulatory pathway	ANDA with Paragraph IV certification
Reference product	Entocort EC
Active ingredient	Budesonide
Dosage form	Delayed-release oral capsules
Core technology	Ileal and colonic delivery of budesonide
Principal legal issue	Obviousness of formulation and treatment claims
Appellate court	U.S. Court of Appeals for the Federal Circuit
Federal Circuit decision	2015

What did the district court decide in Prometheus v. Roxane?

The district court ruled against Prometheus on the asserted claims. The court determined that the claimed budesonide formulation and associated treatment method were obvious in light of the prior art.

The district court’s analysis treated the relevant formulation features as combinations of known elements. Earlier references disclosed budesonide for inflammatory bowel disease, controlled-release delivery, and targeting of the lower gastrointestinal tract. The question was whether a skilled person would have had a reason to combine those teachings with a reasonable expectation of success.

The court found that the prior art supplied the necessary motivation and technical basis. Prometheus argued that the claimed release profile and clinical targeting produced a meaningful improvement over prior formulations. The court rejected that position as insufficient to overcome the prior-art combination.

The ruling meant that Roxane’s ANDA product was not blocked by valid and enforceable patent claims. The decision also weakened the ability to rely on formulation patents to maintain Entocort EC’s market position after expiration of broader product exclusivity.

Why did the Federal Circuit affirm the obviousness ruling?

The Federal Circuit affirmed the district court’s judgment in 2015. The appellate court applied the established framework under 35 U.S.C. § 103 and reviewed the underlying factual findings for clear error while reviewing the ultimate obviousness conclusion as a question of law. [1]

The court’s reasoning centered on four points.

Were the claim elements known in the prior art?

The court found that the relevant technical elements were known. Budesonide had been used to treat inflammatory bowel disease. Controlled-release delivery systems were also established. Earlier work described delivery of medication to the ileum and colon.

The claimed combination did not require an entirely new active ingredient, a new disease indication, or an unconventional dosage form. The patent claims assembled known pharmaceutical and delivery concepts in a field where targeted gastrointestinal release was an active area of research.

Was there a reason to combine the prior-art teachings?

The Federal Circuit agreed that a skilled person would have had a reason to combine the prior art. The combination addressed a recognized clinical and formulation objective: delivering a corticosteroid to the site of Crohn’s disease while reducing exposure in other parts of the gastrointestinal tract.

A predictable combination of known elements can be obvious even when the resulting product has commercial value. The court treated the formulation objective as sufficiently apparent from the prior art.

Did the claimed formulation have a reasonable expectation of success?

The court also accepted the finding that a skilled formulator would have had a reasonable expectation of success. The prior art provided technical direction for using enteric or delayed-release systems to move active drug past the stomach and into the lower gastrointestinal tract.

Prometheus contended that the precise release characteristics were difficult to achieve and that the commercial formulation produced clinical benefits. The Federal Circuit did not treat formulation difficulty or commercial success as enough to establish non-obviousness where the record supported the district court’s prior-art findings.

Did secondary considerations change the result?

Prometheus relied on secondary considerations, including commercial success and the commercial performance of Entocort EC. The court did not find those considerations sufficient to outweigh the evidence of obviousness.

Commercial success has limited evidentiary value when the claimed features are already disclosed or when the success is attributable to unclaimed factors such as marketing, physician familiarity, regulatory approval, or the underlying active ingredient.

What was the Paragraph IV challenge in this case?

Roxane’s ANDA included a Paragraph IV certification challenging the listed Entocort EC patents. The certification gave Prometheus a basis to file a patent-infringement action before commercial generic launch.

The case illustrates the risk profile of Paragraph IV litigation for reformulated products:

1. The innovator may obtain an automatic FDA approval stay by filing promptly.
2. The litigation can preserve the branded product during the case.
3. A final invalidity ruling can remove the principal legal barrier to generic approval.
4. Formulation patents can fail if their release characteristics are predictable from prior art.
5. Method-of-use claims may not protect the product if the claimed clinical objective is already established.

The outcome also demonstrates that an ANDA defendant can prevail without proving that the branded product lacks commercial value. The relevant question is whether the asserted claims are valid and infringed under the patent statutes.

What was the FDA and Orange Book status of Entocort EC?

Entocort EC was approved by the FDA as a prescription budesonide delayed-release capsule for induction of remission in mild to moderate Crohn’s disease affecting the ileum and/or ascending colon. The FDA Orange Book listed patents associated with the reference product and identified applicable regulatory exclusivity information. [2]

The Orange Book listing did not guarantee that the listed patents would survive litigation. A Paragraph IV certification placed validity, enforceability, and infringement directly at issue.

Did FDA approval depend on the patent ruling?

FDA approval of Roxane’s ANDA was subject to the Hatch-Waxman patent stay and the statutory approval provisions governing Paragraph IV certifications. Once the relevant patent barriers were removed or expired, FDA approval could proceed if the ANDA satisfied applicable regulatory requirements.

The Federal Circuit ruling did not itself approve Roxane’s product. It resolved the patent dispute. FDA retained responsibility for determining whether Roxane’s ANDA met requirements concerning chemistry, manufacturing, controls, bioequivalence, labeling, and other regulatory matters.

What was the commercial impact of the Prometheus v. Roxane decision?

The ruling increased generic-entry risk for Entocort EC. Prometheus could no longer rely on the invalidated claims to exclude Roxane through the remaining patent term.

The commercial consequences included:

• Reduced certainty around branded Entocort EC revenue.
• Greater probability of generic substitution.
• Lower value for licensing or acquisition of the challenged patents.
• Increased negotiating leverage for Roxane and other generic applicants.
• Potential price erosion after generic launch.
• Pressure on Prometheus to rely on brand loyalty, supply reliability, contracting, or additional product differentiation.

For a chronic gastrointestinal product, generic entry can affect both price and prescription volume. Pharmacy substitution is particularly important where the generic has the same active ingredient, dosage form, strength, and therapeutic indication.

How strong was the Entocort EC patent estate after the ruling?

The patent estate was materially weakened. The Federal Circuit decision removed the asserted claims as a practical barrier against the Roxane ANDA.

Formulation patent strength

The formulation claims were vulnerable because their key elements were directed to established pharmaceutical objectives:

• Protecting the drug from gastric release.
• Releasing the drug in the intestine.
• Delivering budesonide to the ileum and colon.
• Treating Crohn’s disease with the resulting dosage form.

These objectives were technically predictable based on prior art. The absence of a new active ingredient also made the claims more dependent on narrow formulation distinctions.

Method-of-use patent strength

Method-of-use claims covering treatment of ileal or ileocecal Crohn’s disease faced similar challenges. Where the indication and therapeutic site were already known, a claim that administered a familiar active ingredient through a known delivery system could be vulnerable to an obviousness challenge.

Manufacturing and process barriers

The case did not establish a broad manufacturing exclusivity barrier for budesonide. Manufacturing complexity can delay generic entry, but it does not independently preserve patent exclusivity unless protected by valid process claims or regulatory requirements.

For Entocort EC, the principal legal risk came from formulation and method-of-use patents rather than from a new chemical entity patent.

Which companies were challenging Entocort EC exclusivity?

Roxane was the defendant in this action and challenged the listed patents through its ANDA. The case should be distinguished from other Entocort EC patent actions involving different generic applicants, different ANDAs, or later patent disputes.

A judgment in favor of one ANDA applicant does not automatically resolve every case involving the reference product. Each applicant’s formulation, certification, proposed labeling, and litigation record must be assessed separately. The Prometheus decision nevertheless created an adverse precedent for similar claims directed to delayed-release budesonide formulations.

Did Prometheus and Roxane enter a settlement agreement?

The reported appellate decision reflects an adjudicated patent dispute rather than a settlement-based resolution. The Federal Circuit affirmed the invalidity judgment against Prometheus. No settlement agreement was the basis for the final appellate outcome reported in the case.

A settlement in a separate Entocort EC action would not change the holding in Prometheus v. Roxane. Settlement terms in Hatch-Waxman cases can include launch dates, licenses, supply arrangements, or no-authorized-generic provisions, but those terms are distinct from a final judicial determination that patent claims are invalid.

What generic launch scenarios followed the decision?

The decision supported three principal launch scenarios.

Immediate post-approval generic launch

If Roxane obtained final FDA approval and no independent patent or regulatory barrier remained, it could launch after satisfying the applicable statutory conditions.

Delayed launch based on separate patents

A separate unadjudicated patent, later-filed patent, or distinct formulation claim could delay entry. The Prometheus ruling did not invalidate every possible patent relating to budesonide.

At-risk launch

A generic company could launch while facing residual litigation risk if it concluded that remaining patents were weak, expired, unenforceable, or unlikely to support an injunction. An at-risk launch could expose the company to damages if another valid patent were later found infringed.

What does the case mean for biosimilar risk?

Biosimilar risk was not relevant. Entocort EC contains budesonide, a chemically synthesized small-molecule drug. Roxane proceeded through the ANDA pathway, not the Biologics Price Competition and Innovation Act pathway.

The competitive threat was generic substitution, not biosimilar substitution. The relevant legal tools were Paragraph IV certification, patent litigation under Hatch-Waxman, ANDA approval, and small-molecule bioequivalence.

Key Takeaways

• Prometheus Laboratories v. Roxane involved generic delayed-release budesonide capsules corresponding to Entocort EC.
• Roxane challenged Entocort EC patents through a Paragraph IV ANDA certification.
• The district court held the asserted claims invalid for obviousness.
• The Federal Circuit affirmed the judgment in 2015.
• The court found that the claimed delivery and treatment concepts were predictable combinations of known prior-art teachings.
• Commercial success and formulation difficulty did not overcome the obviousness evidence.
• The decision weakened Prometheus’s formulation and method-of-use exclusivity position.
• The dispute involved generic, not biosimilar, competition.
• FDA approval remained a separate regulatory decision after resolution of the patent case.
• The ruling increased generic-entry and revenue-erosion risk for Entocort EC.

FAQs About Prometheus Laboratories v. Roxane Laboratories

What was the case number for Prometheus Laboratories v. Roxane?

The case was U.S. District Court for the District of New Jersey civil action No. 2:11-cv-00230.

What product was at issue in the case?

The dispute involved Entocort EC, a delayed-release oral budesonide product used to induce remission in mild to moderate Crohn’s disease affecting the ileum and/or ascending colon.

Did Roxane win the patent litigation?

Yes. The district court ruled against Prometheus on the asserted claims, and the Federal Circuit affirmed the resulting judgment.

Was Entocort EC protected by a new-molecule patent?

No. The case involved formulation and treatment-method protection for budesonide, an established corticosteroid, rather than a new chemical entity patent.

Was the case a biosimilar dispute?

No. Roxane challenged the product through the ANDA process for generic drugs. Biosimilar law did not apply.

References

1. U.S. Court of Appeals for the Federal Circuit. (2015). Prometheus Laboratories, Inc. v. Roxane Laboratories, Inc., 805 F.3d 1092.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.